The company manufactures and exports knitted socks for casual, formal, and athletic use, serving both domestic and international markets.
The company lacks a durable moat as evidenced by low single-digit net margins and an average ROCE of 8.6%, which barely covers the cost of capital. While they claim product innovation and quality, the lack of pricing power is reflected in the significant drop in operating margins when input costs fluctuate.
Capital allocation is weak, characterized by reinvestment into a low-return business that has resulted in a negative EPS CAGR of -9.9%. The company maintains a dividend despite declining profitability and poor interest coverage, suggesting a lack of rigorous reinvestment discipline.
The company's inability to service its debt became a terminal spiral as the interest coverage ratio, already at a catastrophic 0.21, failed to recover. Operating margins, which had previously collapsed from over 7% to less than 1%, never regained footing against rising input costs. The business eventually succumbed to a liquidity crisis, exacerbated by capital being drained through related-party loans and dividends that the underlying earnings could not support, leading to a total loss of investor confidence and a forced restructuring.
RichFakir rates Spenta International Ltd's business quality as poor — 16/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Spenta International Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Spenta International Ltd is: Not rated. A poor business at an expensive price — it does not make our shortlist right now. We marked it down a notch: revenue and earnings barely grow — a steady cash cow, not a compounder.
RichFakir's educational estimate of Spenta International Ltd's fair value is about ₹38 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →